Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

November 19th 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.

Dr. Cavnar on the Roles of Chemotherapy and Surgery in Metastatic CRC

November 17th 2020

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Dr. Eng on the Role of Adjuvant Chemotherapy in CRC

November 16th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

CRC Treatment Enters New Era Where Personalized Care Is King

November 16th 2020

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

STING Agonist Plus Atezolizumab Could Expand Immunotherapy Benefit to Nonresponsive Advanced Solid Tumors

November 13th 2020

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

Dr. Cavnar on the Importance of Multidisciplinary Care in CRC

November 10th 2020

Michael J. Cavnar, MD, discusses the importance of multidisciplinary care in colorectal cancer.

Dr. Ahn on the Role of Checkpoint Inhibitors in NTRK Fusion+ MSI-H CRC

November 10th 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Dr. Cavnar on the Management of Liver Metastases in CRC

November 5th 2020

Michael J. Cavnar, MD, discusses the management of patients with liver metastases in colorectal cancer.

Dr. Bekaii-Saab on the Future of Telemedicine in CRC

November 4th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

USPSTF Gives Grade B Recommendation for Lower CRC Screening Age, Lists Cologuard as a Suggested Screening Method

November 3rd 2020

The United States Preventive Services Task Force now recommends that colorectal cancer screening begin 5 years earlier, at age 45 versus age 50, according to new draft guidelines.

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

October 30th 2020

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Dr. Ahn on the Identification of NTRK Alterations in CRC

October 30th 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Dr. Azad on Third-Line Treatment Options in CRC

October 29th 2020

Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Dr. Bahary on the Prognosis of BRAF-Mutant Colorectal Cancer

October 28th 2020

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Dr. Kasi on the Role of MRD Testing in CRC

October 28th 2020

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Dr. Bahary on Treatment Strategies for Right- Versus Left-Sided Tumors in CRC

October 27th 2020

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

October 27th 2020

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors

October 26th 2020

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.